A GROUNDBREAKING study of early treatment of Covid-19 in high-risk patients with ‘The Zelenko Protocol’ (zinc plus low-dose hydroxychloroquine and azithromycin) resulting in decreased hospitalisations by 84 per cent and in a five-fold reduction in death, has been accepted for publication by the International Journal of Antimicrobial Agents after a rigorous peer-review process.
We wrote about Dr Zev Zelenko’s discovery of a way out of the Covid crisis without the aid of a vaccine here. Far from being praised, however, he has come in for a lot of stick. The medical journals have been particularly reluctant to tell the truth about hydroxychloroquine, otherwise known as the anti-malaria drug.
This is all the more of a scandal because the study is unique in that only high-risk out-patients – with a 5 to 10 per cent chance of dying from Covid-19 – were treated with the triple-drug regimen. All were treated at their initial visit, most within the first five days of the onset of symptoms. All had laboratory confirmation of Covid-19 infection.
The results show that of 141 high-risk out-patients who were treated with the triple therapy, only four (2.8 per cent) were hospitalised compared with 15.4 per cent of an untreated control group (58 out of 377). Only one patient died (0.71 per cent) in the treatment group, versus 3.5 per cent (13 out of 377) in the untreated group.
This retrospective analysis is the product of the unique collaboration of three doctors with a rare synergy of industry, academia and clinical medicine. Dr Vladimir Zelenko is board certified in family medicine with 20 years of clinical experience. Dr Roland Derwand is a German physician and life science industry expert. Professor Martin Scholz is an independent consultant and adjunct professor for experimental medicine at Heinrich Heine University, Düsseldorf, Germany. Drs Derwand and Scholz were the first to draw attention to ‘The Zelenko Protocol’ in their published hypothesis paper about the importance of combining zinc with hydroxychloroquine as a method for treating Covid-19.
Dr Derwand said: ‘What differentiates this study is that patients were diagnosed very early with Covid-19 in an outpatient setting, and only high-risk patients were treated early on. Unfortunately, we seem to have forgotten common medical knowledge – that we want to treat any patient with an infectious disease as soon as possible. Dr. Zelenko treated his high-risk patients immediately with the three-drug regimen to ensure sufficient efficacy. He correctly didn’t wait for the disease to further develop.’
Following the rigorous peer-review process, Dr. Zelenko said: ‘It’s unfortunate that much of the media coverage surrounding hydroxychloroquine has been negative. These three medications are affordable, available in pill form, and work in synergy against Covid-19. Hydroxychloroquine’s main role is to allow zinc to enter the cell and inhibit the virus’s reproduction. Azithromycin prevents secondary bacterial infection in the lungs, and reduces the risk of pulmonary complications.’
The third author, Professor Scholz, said: ‘This is the first study with Covid-19 outpatients that shows how a simple-to-perform outpatient risk stratification allows for rapid treatment decisions shortly after onset of symptoms. The well-tolerated five-day triple therapy resulted in a significantly lower hospitalization rate and less fatalities with no reported cardiac side effects compared with relevant public reference data of untreated patients. The magnitude of the results can substantially elevate the relevance of early use, low-dose hydroxychloroquine, especially in combination with zinc. This data can be used to inform ongoing pandemic response policies as well as future clinical trials.’
You can read the full article here.
With acknowledgment to the Internet Protocol.